ArticleJournal for immunotherapy of cancer2019

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Hyun Cheol Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.